Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines

Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines
  • Arcturus Therapeutics Holdings Inc ARCT announced a strategic collaboration with CSL Seqirus, a unit of CSL Limited CSLLY
  • Under the terms of the agreement, Arcturus will provide CSL Seqirus with a license to their self-amplifying mRNA technology to support the research, development, manufacture, and commercialization of vaccines for SARS-CoV-2 (COVID-19), influenza, pandemic-preparedness, as well as three other globally prevalent respiratory infectious diseases.
  • The collaboration combines CSL Seqirus' established global vaccine commercial and manufacturing infrastructure with Arcturus' manufacturing expertise and STARR self-amplifying mRNA vaccine and LUNAR delivery platform technologies.
  • Related Content: Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants
  • CSL Seqirus will lead the development and commercialization of vaccines under the collaboration. 
  • Arcturus will receive $200 million upfront and is eligible to receive over $1.3 billion in development milestones and over $3 billion in commercial milestones. 
  • In addition, Arcturus is eligible to receive a 40% net profit share for COVID-19 vaccine products and up to double-digit royalties for vaccines against flu, pandemic preparedness, and three other respiratory pathogens.
  • Price Action: ARCT shares are up 31.84% at $24.10 during the premarket session on the last check Wednesday.
Posted In: BriefsCOVID-19 CoronavirusCOVID-19 Vaccinepremarket tradingwhy it's movingBiotechNewsHealth CareContractsSmall CapMoversTrading IdeasGeneral